The expansion of a company inevitably hinges on its ability to attract investment and raise capital. Against such a challenging economic backdrop, clients benefit greatly from working with a partner with an unparalleled skillset in equity finance and public offerings. ZAG-S&W is that partner.
Consistently ranked in the first-tier by major domestic and international legal directories, ZAG-S&W’s Corporate and Capital Markets department is a pioneer in Israel, helping clients throughout their lifecycle, from incorporation to going public, expanding internationally or reaching the “exit.”
With a relentless focus on innovation and professionalism of the highest standards, we are a first port of call for public and private companies, as well as founders, investors and underwriters who share this vision.
These clients include public companies in the life sciences sector, with a particular emphasis on medical devices (Endospan, IceCure, Mazor Robotics and Ossio), pharmaceutical companies (PolyPid), clinical stage biopharmaceutical companies (Silenseed and Raziel Therapeutics), biotechnology and biomedical companies (Syqe Medical, Insuline Medical, Kamedis and Pluristem Therapeutics), and many more.
Our comprehensive array of services includes providing ongoing business advice, selecting business partners, building strategic engagements, completing equity financings and public and follow-on offerings.
Our understanding of corporate and securities laws and vast experience in raising capital enable our clients to have access to up-to-the-minute information on regulatory developments, changes in capital raising approaches and much more. Working closely with lawyers in our U.S. and other international offices guarantees that we deliver the timely advice expected by our clients, in their language and in their time zone.